3 New Strong Buy Ratings from Top-Rated Analysts: 02/19/2026
All of these stocks have excellent Zen Ratings — and the backing of Wall Street’s brightest and best.
- Viatris (VTRS) — Buybacks and debt cuts fueling an undervalued comeback
- Tenet Healthcare (THC) — Record hospital demand is sending this stock to multi-year highs
- Hasbro (HAS) — Blockbuster licensing deals spark a 6-year stock high
P.S. Get more alerts like this daily … Try WallStreetZen Premium.
A note from our sponsors...
The ONLY AI opportunity you should be looking at
This is the ONLY AI wealth-building opportunity you should be watching right now.
No. It's not about Nvidia, Tesla, or Meta...
It's about one overlooked company profiting off AI "digital goldmines" that are poised to experience 100x growth very soon.
This new opportunity will change the market and make investors a lot of money.
That's why it has received a $500 billion commitment from President Trump himself...
Learn more about this little-known company here >>>
1. Tenet Healthcare Corp (NYSE: THC)
Recent quarterly earnings surged for this diversified general hospital operator as hospital and surgery demand continues to grow, with the stock hitting multi-year highs following strong Q4 2025 results.
Zen Rating: A (Strong Buy) — see full analysis
Recent Price: $231.10 — get current quote
Max 1-year forecast: $288.00
Why we're watching:
- Analyst support: Impressive coverage from 15 analysts with 13 Strong Buy and 2 Buy ratings reflects overwhelming bullish sentiment on the healthcare provider's trajectory. See the ratings
- Truist Securities' David S Macdonald (a top 9% rated analyst) recently maintained a Strong Buy rating with a $270.00 price target, recognizing the company's strong operational momentum.
- UBS researcher A.J. Rice (top 10%) maintains a Strong Buy with the highest price target of $288.00, representing +22.95% upside potential from current levels.
- Industry ranking context: THC is currently the 9th highest-rated stock in the Medical Care Facility industry, which has an Industry Rating of A, placing it among elite healthcare operators.
- Zen Rating highlights: Strong Buy (A) stocks average +32.52%/yr — THC's positioning in this category reflects strong fundamental and momentum characteristics.
- Component Grades: The stock demonstrates balanced strength with B grades in Value and Financials, supported by solid profitability metrics including a 6.5% profit margin and strong operating cash flow generation. See all 7 Zen Component Grades here
2. Hasbro Inc (NASDAQ: HAS)
The famed toy company's digital pivot is delivering results, with recent announcements of major licensing deals including Harry Potter, K-pop Demon Hunters, and Voltron toys driving the stock to a 6-year high.
Zen Rating: A (Strong Buy) — see full analysis
Recent Price: $102.45 — get current quote
Max 1-year forecast: $118.00
Why we're watching:
- Analyst support: Strong backing from 9 analysts with 7 Strong Buy and 1 Buy rating demonstrates confidence in the company's transformation strategy. See the ratings
- Citigroup researcher James Hardiman (a top 8% rated analyst) recently maintained a Strong Buy rating with a $118.00 price target following the company's Q4 2025 earnings beat and strong fiscal 2026 guidance.
- Industry ranking context: HAS is currently the 2nd highest-rated stock in the Leisure industry, demonstrating its leadership position within the consumer discretionary toy sector.
- Zen Rating highlights: Strong Buy (A) stocks average +32.52%/yr — Hasbro's inclusion reflects its exceptional Growth grade of A and Financials grade of A, with a robust 16.8% profit margin.
- Component Grades: The stock stands out with an A grade in both Growth and Financials, indicating strong earnings momentum and solid balance sheet management despite elevated debt-to-equity ratios typical for consumer brands. See all 7 Zen Component Grades here
3. Viatris (NASDAQ: VTRS)
This global healthcare company is gaining momentum following strategic initiatives focused on buybacks and debt reduction, with analysts highlighting the stock's attractive valuation at current multiples.
Zen Rating: A (Strong Buy) — see full analysis
Recent Price: $15.70 — get current quote
Why we're watching:
- Analyst support: Coverage from 3 analysts with 2 Strong Buy ratings and 1 Hold rating shows emerging positive sentiment. See the ratings
- Argus Research recently upgraded the stock to Strong Buy with a $15.00 price target, expressing confidence that "buybacks and debt reduction should ramp the bottom line" while noting the stock trades at an attractive low multiple.
- Interestingly, the stock has already soared through this projection. This is part of why it was just selected as our Stock of the Week — in his recent commentary, our Zen Investor Editor-in-Chief, Steve Reitmeister, weighed in on several reasons why the stock could continue to outperform.
- Industry ranking context: VTRS is currently the 10th highest-rated stock in the Pharmaceutical industry, which has an Industry Rating of B.
- Zen Rating highlights: Strong Buy (A) stocks average +32.52%/yr — VTRS is among the highest-potential tickers we track in our 4600+ stock database.
- Component Grades: The stock shows balanced strength with B grades in Growth, Momentum, Sentiment, and Safety, indicating solid fundamentals across multiple dimensions. See all 7 Zen Component Grades here
What to Do Next?
Want to get in touch? Email us at news@wallstreetzen.com.
Keep Reading
See All News
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.